Jocelyne Jacquemier

19.6k citations

109 papers · 10.7k indexed · 3 hit papers · h-index 47

Oncology top 0.2%
Molecular Biology top 1%
Cancer Research top 0.1%
Pulmonary and Respiratory Medicine top 1%
Pathology and Forensic Medicine top 0.5%

Co-authors: Daniel Birnbaum Emmanuelle Charafe‐Jauffret Patrice Viens Christophe Ginestier François Bertucci Gabriela Dontu Max S. Wicha Florence Monville
Topics: Breast Cancer Treatment Studies (41 papers)HER2/EGFR in Cancer Research (22 papers)Breast Lesions and Carcinomas (15 papers)
Cited by: Cancer Research Oncology Pathology and Forensic Medicine
Journals: Journal of Clinical Oncology PLoS ONE Cancer
Partner nations: France United States Switzerland

In The Last Decade

Jocelyne Jacquemier

106 papers receiving 10.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical Outcome

2007 3.1k citations Christophe Ginestier, Emmanuelle Charafe‐Jauffret et al. profile →
Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma.

1997 640 citations Jocelyne Jacquemier et al. Journal of Clinical Oncology profile →
Aldehyde Dehydrogenase 1–Positive Cancer Stem Cells Mediate Metastasis and Poor Clinical Outcome in Inflammatory Breast Cancer

2009 575 citations Emmanuelle Charafe‐Jauffret, Christophe Ginestier et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Jocelyne Jacquemier

Since Specialization

Citations

This map shows the geographic impact of Jocelyne Jacquemier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jocelyne Jacquemier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jocelyne Jacquemier more than expected).

Fields of papers citing papers by Jocelyne Jacquemier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jocelyne Jacquemier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jocelyne Jacquemier. The network helps show where Jocelyne Jacquemier may publish in the future.

Co-authorship network of co-authors of Jocelyne Jacquemier

This figure shows the co-authorship network connecting the top 25 collaborators of Jocelyne Jacquemier. A scholar is included among the top collaborators of Jocelyne Jacquemier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jocelyne Jacquemier. Jocelyne Jacquemier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Instant‐quality fluorescence in‐situ hybridization as a new tool for HER2 testing in breast cancer: a comparative study 2013 ·Histopathology ·Camille Franchet,Thomas Filleron,Anne Cayre,(unknown),Frédérique Penault‐Llorca,Jocelyne Jacquemier,Gaëtan MacGrogan,Laurent Arnould,Magali Lacroix‐Triki	9
2	Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors. 2011 ·PubMed ·Marine Gilabert,François Bertucci,Benjamin Esterni,Anne Madroszyk,Carole Tarpin,Jocelyne Jacquemier,Jean-Marc Extra,Patrice Viens,Anthony Gonçalvès	15
3	A gene expression signature identifies two prognostic subgroups of basal breast cancer 2010 ·Breast Cancer Research and Treatment ·Renaud Sabatier,Pascal Finetti,Nathalie Cervera,Éric Lambaudie,Benjamin Esterni,Émilie Mamessier,Agnès Tallet,Christian Chabannon,Jean-Marc Extra,Jocelyne Jacquemier,Patrice Viens,Daniel Birnbaum,François Bertucci	210
4	Aldehyde Dehydrogenase 1–Positive Cancer Stem Cells Mediate Metastasis and Poor Clinical Outcome in Inflammatory Breast Cancerbreakdown → 2009 ·Clinical Cancer Research ·Emmanuelle Charafe‐Jauffret,Christophe Ginestier,Flora Iovino,Carole Tarpin,Mark E. Diebel,Benjamin Esterni,Gilles Houvenaeghel,(unknown),François Bertucci,Jocelyne Jacquemier,Luc Xerri,Gabriela Dontu,Giorgio Stassi,Yi Xiao,Sanford H. Barsky,Daniel Birnbaum,Patrice Viens,Max S. Wicha	575
5	CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines 2009 ·Breast Cancer Research ·(unknown),(unknown),Jocelyne Jacquemier,Pascal Finetti,Thomas Moreau,Benjamin Esterni,Daniel Birnbaum,François Bertucci,Christian Chabannon	122
6	Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer 2009 ·Breast Cancer Research ·Jocelyne Jacquemier,Emmanuelle Charafe‐Jauffret,Florence Monville,Benjamin Esterni,Jean Marc Extra,Gilles Houvenaeghel,Luc Xerri,François Bertucci,Daniel Birnbaum	69
7	Sixteen–Kinase Gene Expression Identifies Luminal Breast Cancers with Poor Prognosis 2008 ·Cancer Research ·Pascal Finetti,Nathalie Cervera,Emmanuelle Charafe‐Jauffret,Christian Chabannon,Colette Charpin,Max Chaffanet,Jocelyne Jacquemier,Patrice Viens,Daniel Birnbaum,François Bertucci	96
8	Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: Prominent expression of P-cadherin 2008 ·BMC Cancer ·(unknown),(unknown),Karima Mrad,Emmanuelle Charafe‐Jauffret,Saïda Ben Arab,Benjamin Esterni,Luc Xerri,Patrice Viens,François Bertucci,Daniel Birnbaum,Jocelyne Jacquemier	28
9	Gene Expression Profiling Shows Medullary Breast Cancer Is a Subgroup of Basal Breast Cancers 2006 ·Cancer Research ·François Bertucci,Pascal Finetti,Nathalie Cervera,Emmanuelle Charafe‐Jauffret,Émilie Mamessier,José Adélaı̈de,Stéphane Debono,Gilles Houvenaeghel,D Maraninchi,Patrice Viens,Colette Charpin,Jocelyne Jacquemier,Daniel Birnbaum	218
10	Prognosis and Gene Expression Profiling of 20q13-Amplified Breast Cancers 2006 ·Clinical Cancer Research ·Christophe Ginestier,Nathalie Cervera,Pascal Finetti,Séverine Esteyriès,Benjamin Esterni,José Adélaı̈de,Luc Xerri,Patrice Viens,Jocelyne Jacquemier,Emmanuelle Charafe‐Jauffret,Max Chaffanet,Daniel Birnbaum,François Bertucci	107
11	Protein Expression Profiling Identifies Subclasses of Breast Cancer and Predicts Prognosis 2005 ·Cancer Research ·Jocelyne Jacquemier,Christophe Ginestier,Jacques Rougemont,Valérie‐Jeanne Bardou,Emmanuelle Charafe‐Jauffret,Jeannine Geneix,José Adélaı̈de,Alane Koki,Gilles Houvenaeghel,J Hassoun,D Maraninchi,Patrice Viens,Daniel Birnbaum,François Bertucci	174
12	Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy 2005 ·Oncogene ·Anthony Gonçalvès,(unknown),François Bertucci,R Sauvan,(unknown),Myriam Cubizolles,V J Bardou,(unknown),Jocelyne Jacquemier,Samuel Granjeaud,(unknown),Eileen Fung,Daniel Birnbaum,D Maraninchi,Patrice Viens,Jean‐Paul Borg	102
13	A Recurrent Chromosome Breakpoint in Breast Cancer at the *NRG1* / *Neuregulin 1* / *Heregulin* Gene 2004 ·Cancer Research ·(unknown),Suet‐Feung Chin,Christophe Ginestier,Valérie‐Jeanne Bardou,José Adélaı̈de,N. Gopalakrishna Iyer,María J. García,Jessica C. Pole,Grace Callagy,Stephen M. Hewitt,William J. Gullick,Jocelyne Jacquemier,Carlos Caldas,Max Chaffanet,Daniel Birnbaum,Paul A. Edwards	73
14	Local and distant failures after limited surgery with positive margins and radiotherapy for node-negative breast cancer 2000 ·International Journal of Radiation OncologyBiologyPhysics ·D. Cowen,Gilles Houvenaeghel,(unknown),Jocelyne Jacquemier,Éric Bautrant,(unknown),Patrice Viens,R. Largillier,Brigitte Puig,M. Resbeut,D Maraninchi	58
15	Local and distant recurrence after conservative management of “very low-risk” breast cancer are dependent events: a 10-year follow-up 1998 ·International Journal of Radiation OncologyBiologyPhysics ·D. Cowen,Jocelyne Jacquemier,Gilles Houvenaeghel,Patrice Viens,Brigitte Puig,Valérie‐Jeanne Bardou,M. Resbeut,D Maraninchi	51
16	[Modalities of reading of detection mammographies of the programme in the Bouches-du-Rhône. Results and costs 1990-1995]. 1997 ·PubMed ·B. Séradour,Suzanne Wait,Jocelyne Jacquemier,Myriam Dubuc,L Piana	10
17	The heregulin gene can be included in the 8p12 amplification unit in human breast cancer 1994 ·Genes Chromosomes and Cancer ·(unknown),Frédérique Penault‐Llorca,(unknown),Yosef Yarden,Jocelyne Jacquemier,Daniel Birnbaum	6
18	Expression of the FGFR1 gene in human breast‐carcinoma cells 1994 ·International Journal of Cancer ·Jocelyne Jacquemier,José Adélaı̈de,Patricia Parc,Frédérique Penault‐Llorca,J Planche,Odile deLapeyrière,Daniel Birnbaum	68
19	FGFRI and PLAT genes and DNA amplification at 8p 12 in breast and ovarian cancers 1993 ·Genes Chromosomes and Cancer ·Charles Theillet,José Adélaı̈de,Geneviève Louason,Françoise Bonnet‐Dorion,Jocelyne Jacquemier,Jalila Adnane,Michel Longy,(unknown),P Sismondi,Patrick Gaudray,Daniel Birnbaum	131
20	Why are local recurrences after breast-conserving therapy more frequent in younger patients? 1990 ·Journal of Clinical Oncology ·Julia Kurtz,Jocelyne Jacquemier,R. Amalric,H Brandone,Y Aymé,Daniel Hans,C Bressac,J M Spitalier	205

About Jocelyne Jacquemier

Jocelyne Jacquemier is a scholar working on Cancer Research, Oncology and Pathology and Forensic Medicine, having authored 109 papers that have together received 10.7k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (41 papers), HER2/EGFR in Cancer Research (22 papers) and Breast Lesions and Carcinomas (15 papers). The work is most often cited by research in Cancer Research (4.4k citations), Oncology (6.2k citations) and Pathology and Forensic Medicine (1.7k citations). Jocelyne Jacquemier has collaborated with scholars based in France, United States and Switzerland. Frequent co-authors include Daniel Birnbaum, Emmanuelle Charafe‐Jauffret, Patrice Viens, Christophe Ginestier, François Bertucci, Gabriela Dontu, Max S. Wicha, Florence Monville, Suling Liu and Celina G. Kleer. Their work appears in journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact